43 results about "Metabolic profile" patented technology

The invention is applicable to the technical field of biology, and provides edible lactobacillus for relieving pulmonary fibrosis and application thereof, the edible lactobacillus for relieving pulmonary fibrosis provided by the embodiment of the invention is named as lactobacillus plantarum ZYHL3, is preserved in China Center for Type Culture Collection (CCTCC), has a preservation number of CCTCC No: M 2025127, has a preservation number of CCTCC No: M 2025127, and has a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, a preservation number of CCTCC No: M 2025127, and a preservation number of CCTCC No: M 2025127. Lung inflammation and pulmonary fibrosis of mice can be remarkably relieved and disease prognosis can be improved by adjusting intestinal flora diversity and metabolic profiles, so that a new thought can be provided for preventing and treating pulmonary fibrosis diseases such as idiopathic pulmonary fibrosis and the like.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

Provided in the present invention are a global metabolic profile inference method and apparatus, and a lung cancer prediction model construction method and apparatus. The global metabolic profile inference method comprises: obtaining original chromatography-mass spectrometry data of a target sample; using a filter to perform, in a three-dimensional point cloud space, a convolution operation on data that is obtained by performing conversion on the basis of the original chromatography-mass spectrometry data, so as to down-sample the data into a two-dimensional matrix; on the basis of the two-dimensional matrix, constructing mask images having a plurality of mask proportions and a size consistent with the size of the two-dimensional matrix, so as to form a mask image library; and selecting a plurality of target mask images from the mask image library, multiplying each target mask image by the two-dimensional matrix, inputting same into a trained mass spectrometry inference model based on a convolutional neural network to perform disturbance prediction, and on the basis of the disturbance prediction, obtaining retention information of a sample corresponding to the currently input two-dimensional matrix, so as to infer a global metabolic profile of a metabolite in the target sample.

The invention discloses a rapid detection method for bloodstream infection pathogenic bacteria based on a rapid mass spectrometry technology, and belongs to the technical field of medical detection. Analyzing the metabolic gas of the blood flow infected pathogenic bacteria by using UVP-TOFMS to obtain a pathogenic bacteria metabolic profile spectrogram; preprocessing the obtained pathogenic bacterium metabolism profile spectrogram data; integrating the preprocessed pathogenic bacterium metabolism profile spectrogram data by using a stacking algorithm, and constructing a pathogenic bacterium identification model; evaluating the effectiveness of the pathogenic bacterium identification model on a training set and a test set through accuracy, precision, a confusion matrix and a subject operation curve; and comparing and screening characteristic metabolic markers of the pathogenic bacteria by combining the importance and significance of model characteristics, and indicating the types of the pathogenic bacteria. The method does not need sample pretreatment, is simple and convenient to operate, short in detection time (20 seconds per sample), high in accuracy and suitable for clinical popularization, and provides technical support for early diagnosis and treatment of bloodstream infection.

The invention relates to a method of diagnosing a subtype of autism spectrum disorder (ASD), so called ASD Phenotype 1, by assessing the energy production capacity of patient specific cell lines in presence of various carbon sources of energy and metabolic factors or by assessing the changes in energy production capacity or lack thereof after administration of an Nrf2-inhibitor.

The invention provides a pulmonary nodule targeting food and medicine homologous composition based on metabonomics screening and application thereof. By analyzing a pulmonary nodule specific metabolic profile, active components, namely platycodin D, mogroside V, oyster active peptide and fermented cordycepin, which can cooperatively regulate and control an arachidonic acid inflammation pathway, a glutathione antioxidant pathway and a tricarboxylic acid cycle energy pathway are reversely screened out. Animal experiments prove that the composition can reduce the volume of pulmonary nodules by 58.3%, human body application shows that the nodules of 76.7% of subjects are reduced, and liver and kidney toxicity is avoided. The composition can be prepared into tablets, capsules and other dosage forms, can be used as functional food or adjuvant therapy drugs for high risk groups of pulmonary nodules, and realizes accurate nutrition intervention.

This invention discloses a pharmaceutical composition for treating asthenospermia by activating the Nrf2 / HO-1 / GPx4 pathway and its application. The pharmaceutical composition comprises taurine and geranium as active ingredients, wherein the mass ratio of taurine to geranium is 3-5:1. The pharmaceutical composition of this invention can synergistically activate the Nrf2 / HO-1 / GPx4 antioxidant signaling pathway, upregulate the expression of downstream antioxidant enzymes GPx4 and HO-1, inhibit lipid peroxidation, protect sperm mitochondrial function, and simultaneously improve the microenvironmental metabolic profile of the epididymis—the site of sperm maturation—thereby enhancing sperm motility. The pharmaceutical composition provided by this invention can be used to prepare a treatment for asthenospermia, particularly oxidative stress-induced asthenospermia.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform receives patient data recorded during the current time period comprising food items consumed, medications taken, and symptoms experienced by the patient. The platform implements a machine-learned metabolic model to determine a metabolic state of the patient at a conclusion of the current time period by comparing a true representation of the metabolic state and a prediction of the metabolic state. The true representation and the prediction are determined based on the recorded biosignals and the recorded patient data, respectively. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve their metabolic state and provides the patient-specific treatment recommendation to the patient device for display to the patient.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and / or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and / or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.

According to the compound anti-tumor screening method provided by the invention, a cell metabolism phenotype model, namely a D-lactic acid cell model, is established, and a compound capable of reducing abnormal change of metabolite content induced by D-lactic acid is screened by taking a cell metabolism profile as a detection index. According to the method, a progressive evaluation system from in-vitro metabonomics screening to in-vivo pharmacodynamic verification is adopted, compounds influencing the change of the metabolite content of cells are effectively recognized and evaluated, the limitation of traditional tumor drug screening is broken through, the cell metabolism change caused by D-lactic acid is focused, the targeting property and reliability of anti-cancer drug development are remarkably improved, and the method is suitable for clinical application. And an innovative technical path is provided for treating tumors related to abnormal metabolism.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

A patient health management platform accesses a metabolic profile for a patient and biosignals recorded for the patient during a current time period comprising sensor data and / or lab test data collected for the patient. The platform encodes the biosignals into a vector representation and inputs the vector representation into a patient-specific metabolic model to determine a metabolic state of the patient at a conclusion of the current time period. The patient-specific metabolic model comprises a set of parameter values determined based on labels assigned to the previous metabolic states and a function representing one or more effects of the plurality of biosignals of the personalized metabolic profile. The platform compares the determined metabolic state of the patient to a threshold metabolic state representing a target metabolism. The platform generates a patient-specific treatment recommendation outlining instructions for the patient to improve the determined metabolic state to the functional metabolic state.

The invention discloses a group of diagnosis, typing and prognostic markers for children Langerhans cell histocytosis, and belongs to the technical field of disease diagnosis. In the invention, an overall metabolic profile of bone marrow aspirates (BMA) of 34 children LCH patients is analyzed, and the patients are divided into three subtypes: single system diseases (SS), multi-system diseases (MS-RO-) without dangerous organ tiredness and multi-system diseases (MS-RO +) with dangerous organ tiredness. The metabonomics characteristics of children diagnosed as LCH are described, the metabolic characteristics of a multi-system LCH (MS-RO +) group with dangerous organs being tired before and after treatment are comprehensively researched, and important metabolic markers for molecular diagnosis, subtype classification, treatment evaluation and prognosis are provided for children patients suffering from LCH, especially high-risk LCH.

This dual-compartment liver co-culture system exposes target microtissue to metabolites, allowing for evaluating toxicity using a standard multi-well plate for high throughput analysis. Discovery scientists can rapidly select lead compounds with desirable metabolic profiles, while safety scientists can determine the safety of drugs, pesticides, and environmental chemicals. This platform is allometrically scalable, so it can mimic the natural size differences between healthy organs and, with the liver, produce sufficient quantities of metabolites. The device is simple to use and designed for immediate in vitro pathology assessment using confocal microscopy, transcriptomics, and proteomics.

The invention relates to a method for noninvasively evaluating age-dependent metabolic characteristics of mouse oocytes. The method comprises the following steps: S1, collecting oocytes of mice at different month ages; s2, treating the oocytes to obtain a sample capable of being used for spontaneous Raman spectroscopy and imaging; s3, performing spontaneous Raman spectroscopy and imaging of different oocytes; s4, processing and analyzing Raman spectrum data; s5, processing and analyzing two-dimensional and three-dimensional Raman imaging; s6, analyzing morphological and spectral characteristics of oocytes of mice of different age groups; and S7: determining the specific age-related change of the lipid content and distribution, the cytochrome c level and the metabolic profile in the mouse oocytes. Compared with the prior art, the method has the advantages that the metabolic change of the oocytes of mice with different maternal ages is analyzed by Raman spectrum for the first time, the age-dependent distribution change of lipid and cytochrome c is revealed through high-resolution subcellular mapping, and a new research scheme is provided for the biochemical mechanism of oocyte senescence.

In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.

The present disclosure involves a method and nutritional composition for improving the microbiome and metabolic profile of a pediatric subject, which includes administering to a pediatric subject a composition having up to about 7 g / 100 kCal of a protein or protein equivalent source; up to about 7 g / 100 kCal of a fat or lipid source; at least about 5 g / 100 kCal of a carbohydrate; at least about 0.05 mg / 100 kCal of bacterial metabolites; and either a probiotic or a prebiotic composition, or both.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

A pharmaceutical composition comprises a muscarinic agonist and a pharmacokinetic (PK) modifier that changes the metabolic profile the muscarinic agonist. The pharmaceutical composition may be used for the treatment of a neurological disorder or condition in a subject.

In some aspects, provided herein are methods for treating a liver disease or associated condition in a subject, and related compositions. In some embodiments, the composition comprises lactulose and a commensal organism, such as a commensal bacterial species. In some embodiments, the patient has been determined to have a microbiome profile and metabolic profile in a fecal sample from the patient, which may be indicative that the patient will benefit from the treatment.

Embodiments of the present disclosure may include an implantable device (100) for in vivo measurement of metabolites, including a laser diode (110) or an IR diode (120) or optical waveguide as an external (outside body) light source with a laser diode (110) or an IR diode (120) for Raman spectroscopy unit (140). Embodiments may also include an optical filter (130) that filters the scattered light. Embodiments may also include a Raman spectroscopy unit (140) for detecting the metabolic profile of a subject. Embodiments may also include a Fabry-Pérot interferometer (150) with a spherical mirror, functioning as an etalon, for refining the detection of Raman scattering signals. Embodiments may also include a CMOS sensor (160) for capturing the refined Raman scattering signals. Embodiments may also include a piezo element (170a) or MEMS actuator (170b) for actuating the Fabry-Pérot interferometer (150). Embodiments may also include MCU (180) as a controller and a processing unit.

The invention relates to a detection method for establishing a brucella infected serum metabolic map based on laser dissociation mass spectrometry, which comprises the following steps: step 1, performing metabolism detection on serum samples of brucellosis patients and healthy volunteers by using an iron nanoparticle-assisted laser desorption ionization mass spectrometry technology to obtain a serum metabolism fingerprint map; step 2, carrying out various model training on a serum sample by adopting a machine learning algorithm on the serum metabolism fingerprint spectrogram obtained in the step 1, evaluating various models through a cross validation method, and screening a final diagnosis model according to a validation result; and step 3, diagnosing serum samples of brucellosis patients and healthy volunteers according to the diagnosis model in the step 2, and screening metabolic biomarkers in the serum samples according to a diagnosis result. According to the marker combination, the detection process is rapid and simple, the result is accurate and reliable, and the screened metabolic biomarker can be used for diagnosing brucellosis.

There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and / or delivery efficiency of a drug or prodrug, as well as its therapeutic or prophylactic efficacy and / or adverse effects. Use of the isotope-enriched amide-containing drugs and prodrugs for the treatment or prevention of disease states and conditions is also provided.

The invention relates to a neonatal genetic disease gene and metabolite combined screening method, system and equipment, and the method comprises the steps: carrying out the rapid detection of a plurality of metabolites on a neonatal biological sample, and obtaining metabolic spectrogram data; comparing the metabolic spectrogram data with a metabolic phenotype-genotype associated knowledge base, and automatically identifying an abnormal metabolic phenotype meeting a preset condition; in response to the identified abnormal metabolic phenotype, automatically triggering gene analysis of a specific gene corresponding to the target genetic disease in the same biological sample; based on the abnormal metabolic phenotype and the gene analysis result of the specific gene, a combined screening report is generated, so that accurate and efficient source tracing from a non-specific metabolic disorder index to a specific pathogenic gene source is achieved, and the purpose of providing an integrated screening and auxiliary diagnosis solution for neonatal genetic diseases is achieved.

The present invention discloses a method and system for screening bladder cancer metabolic markers based on deep learning. Starting from the encoded features based on the variational autoencoder network, combined with backpropagation to sort the weight values, threshold conditions are set for screening the mass-to-charge ratio features, greatly reducing the feature dimension; a method for imputing missing values based on sample similarity is proposed, mainly using fuzzy C-means clustering, K-nearest neighbor method and iterative imputation based on Bayesian ridge regression to impute missing values, which is beneficial to improving the performance of subsequent data mining and shortening the imputation time. The features screened by the neural network are processed using the recursive feature elimination method to reduce its computational complexity. The mass-to-charge ratios of the metabolite ions obtained by screening are reflected in the published reports, and the sensitivity, specificity and area under the curve (AUC) of this set of mass-to-charge ratio features are all greater than 0.9, which can accurately reflect the metabolic profile differences between bladder cancer patients and healthy individuals.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's blood pressure. The platform implements a short-term prediction model to generate a daily prediction of the patient's blood pressure based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's blood pressure during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's diastolic and systolic blood pressure and updates a digital twin of the patient's metabolic profile.

A patient health management platform implements a machine-learned metabolic model to generate a prediction of a patient's glucose level. The platform implements a short-term prediction model to generate a daily prediction of the patient's glucose level based on nutrition data reported by the patient and sensor data and lab test data collected for the patient. The platform implements a long-term prediction model generate a prediction of the patient's glucose level during an extended time period based on sensor data and lab test data collected for the patient. Using the short-term prediction model, the long-term prediction model, or both, the patient health management platform generates predictions of the patient's glucose level and updates a digital twin of the patient's metabolic profile.

Embodiments of the present disclosure may include an implantable device (100) for in vivo measurement of metabolites, including a laser diode (110) or an IR diode (120) or optical waveguide as an external (outside body) light source with a laser diode (110) or an IR diode (120) for Raman spectrometry unit (140). Embodiments may also include an optical filter (130) that filters the scattered light. Embodiments may also include a Raman spectroscopy unit (140) for detecting the metabolic profile of a subject. Embodiments may also include a Fabry-Pérot interferometer (150) with a spherical mirror, functioning as an etalon, for refining the detection of Raman scattering signals. Embodiments may also include a CMOS sensor (160) for capturing the refined Raman scattering signals. Embodiments may also include a piezo element (170a) or MEMS actuator (170b) for actuating the Fabry-Pérot interferometer (150). Embodiments may also include MCU (180) as a controller and a processing unit.